<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study compared the effects of ATP-regulated <z:chebi fb="120" ids="26216">potassium</z:chebi> channel (K(ATP)) openers, <z:chebi fb="0" ids="4495">diazoxide</z:chebi> and pinacidil, on diseased and <z:mpath ids='MPATH_458'>normal</z:mpath> human atria and ventricles </plain></SENT>
<SENT sid="1" pm="."><plain>We optically mapped the endocardium of coronary-perfused right (n=11) or left (n=2) posterior atrial-ventricular free wall preparations from human hearts with <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>, n=8) and non-failing human hearts without (NF, n=3) or with (INF, n=2) infarction </plain></SENT>
<SENT sid="2" pm="."><plain>We also analyzed the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of the K(ATP) targets K(ir)6.1, K(ir)6.2, SUR1, and SUR2 in the left atria and ventricles of NF (n=8) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> (n=4) hearts </plain></SENT>
<SENT sid="3" pm="."><plain>In both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and INF hearts, <z:chebi fb="0" ids="4495">diazoxide</z:chebi> significantly decreased action potential durations (APDs) in atria (by -21±3% and -27±13%, p&lt;0.01) and ventricles (by -28±7% and -28±4%, p&lt;0.01) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="4495">Diazoxide</z:chebi> did not change APD (0±5%) in NF atria </plain></SENT>
<SENT sid="5" pm="."><plain>Pinacidil significantly decreased APDs in both atria (-46 to -80%, p&lt;0.01) and ventricles (-65 to -93%, p&lt;0.01) in <z:hpo ids='HP_0000001'>all</z:hpo> hearts studied </plain></SENT>
<SENT sid="6" pm="."><plain>The effect of pinacidil on APD was significantly higher than that of <z:chebi fb="0" ids="4495">diazoxide</z:chebi> in both atria and ventricles of <z:hpo ids='HP_0000001'>all</z:hpo> groups (p&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>During pinacidil perfusion, burst pacing induced flutter/<z:mp ids='MP_0006109'>fibrillation</z:mp> in <z:hpo ids='HP_0000001'>all</z:hpo> atrial and ventricular preparations with dominant frequencies of 14.4±6.1 Hz and 17.5±5.1 Hz, respectively </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="5441">Glibenclamide</z:chebi> (10 μM) terminated these <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and restored APDs to control values </plain></SENT>
<SENT sid="9" pm="."><plain>Relative <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels of K(ATP) targets were correlated to functional observations </plain></SENT>
<SENT sid="10" pm="."><plain>Remodeling in response to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and/or previous <z:mpath ids='MPATH_124'>infarct</z:mpath> potentiated <z:chebi fb="0" ids="4495">diazoxide</z:chebi>-induced APD shortening </plain></SENT>
<SENT sid="11" pm="."><plain>The activation of atrial and ventricular K(ATP) channels enhances arrhythmogenicity, suggesting that such activation may contribute to reentrant <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> in ischemic hearts </plain></SENT>
</text></document>